Hosted on MSN1d
Possibility of Trump's call for SMA deal renegotiation can't be ruled out: Seoul envoyThe possibility of former President Donald Trump demanding renegotiation of a new defense cost-sharing deal between South ...
Spinal muscular atrophy (SMA) is a rare genetic disorder that causes muscle weakness and disability, typically in young ...
Researchers have discovered biomarkers for diverse forms of spinal muscular atrophy (SMA) following applications of ...
A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus ...
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...
Zacks.com on MSN4d
NUS Stock Trading Below 200 & 50-Day SMA: What Should You Do Now?Nu Skin Enterprises, Inc. NUS has been seeing a rough patch, consistently trading below its 200-day and 50-day simple moving ...
Scholar Rock aims for a significant market presence with apitegromab in spinal muscular atrophy. See more on SRRK stock and ...
In the SAPPHIRE trial, Scholar Rock tested apitegromab in patients aged two to 12 who were already being treated with the ...
The Jakarta Education Agency has defended the decision to hold a free nutritious meals program trial at SMA 70 public senior ...
A retrospective analysis on newborn screening for spinal muscular atrophy (SMA) provides further evidence for the benefits of ...
SMA Australia is proud to announce that its parent company SMA has achieved ISO 27001 certification for its innovative Sunny Portal PV system monitor.
Scholar Rock Holding Corporation (NASDAQ:SRRK)近期经历了显著的市场动力，与文章中强调的积极临床试验结果相一致。InvestingPro数据显示，过去一周股价回报率高达252.29%，过去一个月回报率为200.81%，反映了投资者对公司前景的强烈热情。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback